On Demand Training

Save on travel expenses, and learn on your own schedule.

ISPE’s On Demand training includes recorded conference sessions, instructional lead courses and webinars to help you expand your skills and knowledge from the comfort of your desk.


ISPE Best of Pharma Series

No need to miss out on valuable knowledge-sharing! ISPE has gone through all of our conference presentations from 2020, hand-selected the absolute best and brightest, and packaged it into the ISPE Best of Pharma Series. Access the most premier presentations offering compelling insights, strategies, and best practices from experts representing global health authorities and leading pharma organizations.


Presentations are divided between four critical areas of pharma, allowing you to select the topic-specific package that is most pertinent to your knowledge needs:

Biotechnology

Biotechnology
21 Presentations Featuring 8+ Hours of Content

Learn More

Cell & Gene Therapy

Cell & Gene Therapy
30 Presentations Featuring 11+ Hours of Content

Learn More

Continuous Manufacturing

Continuous Manufacturing
14 Presentations Featuring 5+ Hours of Content

Learn More

Regulatory

Regulatory
39 Presentations Featuring 18+ Hours of Content

Learn More


Additional On Demand Training Opportunities

  • Additional Recorded Conference Sessions

    ISPE teams up with presenters from various conferences to record presentations that address a wide range of topics pertinent to global pharmaceutical professionals.

    The recorded session packages are an ideal opportunity to gain valuable information from new technology, product development, case studies with in-depth knowledge, and best practices all without leaving your desk. View Recorded Sessions


    Featured Conference sessions

    2020 ISPE Biopharmaceutical Manufacturing Virtual Conference Sessions

    Biovc20

    The 2020 ISPE Biopharmaceutical Manufacturing Virtual Conference focused on innovation in facilities, production methods, and technologies that enable a competitive and sustainable biopharmaceutical product supply for the future. This conference brought together experts that are developing, implementing, and operating advanced supply chains providing high quality medicines to global markets.

    If you missed the conference, this is your opportunity to gain access to all of the educational content from the conference and view it on your own schedule. Get the biggest bang for your buck by purchasing the entire conference in one package or review the list of sessions to purchase individual.

    2020 ISPE Biopharmaceutical Manufacturing
    Virtual Conference Sessions

    All purchases include access to the plenary sessions

      Per Session Package
    Member $199   $1,295  
    Nonmember   $249    $1,850
    Government/Academia* N/A $500  
    Student* N/A $90  

    Conference Sessions

    • Cell & Gene Therapy Sessions

      Cell and Gene Therapy CMC and Manufacturing

      Cell and Gene Therapy CMC and Manufacturing: Ensuring the Analysis, Production and Quality Robust and cost-effective characterization and manufacturing presents a core challenge in the commercialization of gene and cell therapies with pressure mounting on CMC, analytical and manufacturing teams to keep up with accelerated development times and cost pressures. Gene and Cell Therapy CMC and Manufacturing examines the critical challenges facing the production, characterization and quality control of gene and cell therapies, with dedicated presentations on rapid CMC development, product and process characterization, upstream and downstream bioprocessing and considerations for personalized and large-scale manufacturing.

      • Transformation from R&D to Manufacturing
        James Warren, PhD, Vice President Pharmaceutical Development
        Ultragenyx
      • Re-thinking Comparability Assessments for Individualized Therapeutics?
        Kathy Francissen, PhD, Senior Director, Pharma Technical Regulatory
        Genentech, A Member of the Roche Group
      • Virtual Inspections: Navigating the New Paradigm
        Monica M. Commerford, PhD, Manager of Regulatory Affairs
        Brammer Bio

      Planning, Building and Operating Cell and Gene Therapy

      Planning, Building and Operating Cell and Gene Therapy Facilities (Part I) Many cell and gene therapy facilities are in different phases of planning, construction, and expansion.  Learn from experts in engineering and manufacturing about how these facilities are progressing. This two-session track will explore various designs as we move from lab scale to higher volume production; control for single use to allow for multiple manufacturing trains. These sessions will examine going from manual to automated processing to meet the demand and the various technologies and layouts being utilized to supply patient needs and meet regulatory GMP requirements.  

      • Building Flexibility for Multiple Cell Therapy Processes
        Daniel Swanson, Senior Project Engineer Biopharmaceutical Pilot Plant
        GlaxoSmithKline  
      • Leveraging Operational Simulations for Gene Therapy Facilities
        Niranjan Kulkarni, PhD, Director, Operations Improvement
        CRB

      Planning, Building and Operating Cell and Gene Therapy

      Planning, Building and Operating Cell and Gene Therapy Facilities (Part II) Many cell and gene therapy facilities are in different phases of planning, construction, and expansion.  Learn from experts in engineering and manufacturing about how these facilities are progressing.   This two-session track will explore various designs as we move from lab scale to higher volume production; control for single use to allow for multiple manufacturing trains. These sessions will examine going from manual to automated processing to meet the demand and the various technologies and layouts being utilized to supply patient needs and meet regulatory GMP requirements.  

      • ATMP Facility Scale-up to Production using Isolator Technology
        Michael Hennessy Head of Global Sales
        ProSys Group  
      • The Impact of Innovation on Building the Facilities of the Future
        John Khoury, Principal Engineer
        ProjectFarma
        Alexis Melendez, Director of Engineering and Facilities Kite
        Pharma, Inc.

      Practical Challenges With Quality System Management

      Practical Challenges with Quality System Management in Cell and Gene Therapies This session will focus on the challenges with the establishment of quality oversight and systems from the initial patient interface through manufacturing and supply for cell and gene therapies.  Experience with the application of cGMPs in the hospital setting will be discussed as well as the conflicting priorities when multiple companies are imposing different demands on the same institutions, notably as these controls are part of the approved applications. The efforts to harmonize standards globally, as well as the regulator experience in determining true compliance risks will be addressed.  

      • FDA Perspective on GMPs for Cell & Gene Therapies
        Ekaterina Allen, PhD, RAC, Regulatory Project Manager & CMC Facilities Reviewer,
        FDA/CBER  
      • Quality Considerations for Cell & Gene Therapy
        Luciana Mansolelli, Head Quality Strategic Planning, Cell & Gene Technical Development & Manufacturing
        Novartis
      • Challenges for GMPs for ATMPs: European Perspective
        Lina Ertle, Head of External Relations EMEA &
        Japan, Roche
    • Digitalization Sessions

      Increased Automation and Digitalization in Manufacturing

      Increased Automation and Digitalization in Manufacturing Computer systems have continued to help manage complexity involved in biopharmaceutical manufacturing.  Such systems have evolved in ways previously not anticipated.  This session will explore some of the evolving uses of computer systems to allow a greater focus on product quality.  

      • BioPhorum Plug and Play: Developing and Utilizing Standards to Enable Reduced Project Delivery Time
        Bruce Kane, P.E. Global Life Science Technical Consultant
        Rockwell  
      • Automation How Digital is Transforming Quality Assurance Operations: A Focus on Real and Right Time Release
        Michael Shanno, Head of Digital and IT Biologics Quality
        Sanofi
      • The Digital Twin: Integrated Engineering the Key to Cost-Effective Digitalization
        Martin Mayer, Business Development
        ZETA
    • Drug Products Sessions

      Technology Advancements for Drug Product Manufacturing

      Technology Advancements for Drug Product ManufacturingThis session will discuss technology advances related to the manufacturing of biologic drug products of different dosage forms.  Technologies and case studies to be discussed include low temperature sealing of container closures and continuous aseptic spray freeze-drying. 

      • Dynamic Challenge Sealing Performance for Biologic Container Systems at Low Temperature
        Qingyu Zeng, PhD, Fellow, Technical Director
        West Pharmaceutical Services, Inc.  
      • Single-Use Technology for Final Fill: An Overview
        Laura Moody, PhD, Product Manager – Primary Packaging Pharma Liquid Packaging, North America,
        Syntegon Pharma Technology LLC
      • Vial Visualization Using AI
        Joshua Stauffer, Staff Engineer
        Merck & Co., Inc.
    • Pharma 4.0 Sessions

      Pharma 4.0: What it is, What it isn’t

      Pharma 4.0: What it is, What it isn’t and How to Implement itTrying to figure out what Pharma 4.0 is and what it means to your business? This session will clarify what Pharma 4.0 is and offer practical aspects of how it has been implemented in the plant and what it means to your workforce.

      • Why Pharma 4.0? Did We Advance?
        Christian Woelbeling, Senior Director Global Accounts
        Werum IT Solutions  
      • Enabling Automation and Pharma 4.0 in Cell Therapy
        Laura Moody, PhD, Product Manager – Primary Packaging
        Shin Kawamata, Director of R&D Centre for Cell Therapy
        Foundation for Biomedical Research and Innovation (FBRI)
        David Margetts, CEO
        Factorytalk, Co. Ltd.
      • Pharma 4.0 Meets Operator 4.0: Facing Knowledge Challenges of Manufacturing in the 4.0
        Era Patrick Boyle, President
        SkillPad Canada Inc.
    • Plenary Sessions - Bonus Content Included

      Innovation in Technological Platforms in Biopharmaceutical

      Plenary Session - Innovation in Technological Platforms in Biopharmaceutical Manufacturing As described in the morning session, regulatory expectations continue to evolve given the complexities associated with new products and innovation. This session will provide an opportunity to hear more about this topic in the context of an innovative vaccine facility and related sterile manufacturing requirements.

      • Process and Facility Innovation using PODs in Vaccine Manufacturing – Benefits and Challenges
        Maria Hoffman, Executive Director, Supply Chain Management
        Merck  
      • Innovations in Sterile Manufacturing – Regulatory Considerations
        Patricia Hughes, PhD, Branch Chief, Division of Microbiology Assessment
        CDER, FDA

      Opening Plenary

      Opening Plenary - Challenges and Opportunities in the Manufacturing of New Treatment Modalities This year, the 2020 ISPE Biopharmaceutical Manufacturing Conference will focus on advances in manufacturing, facilities, and analytics important to bring new therapies to patients. Now more than ever, manufacturing is on the critical path as many new treatments in the area of personalized medicines and individualized batch production present the challenge to bring these medicines through rapid development, reliable manufacturing, and availability to patients a pace with the advances clinical research is bringing to address unmet needs. At the same time, biosimilars are advancing with the opportunity to provide more access to medicines.  In this opening session, we will hear an important regulatory perspective from FDA on gene therapy drug development and a reflection from industry on 10 years of Biosimilars.


      Regulatory and Industry Insights & Lessons Learned

      Closing Plenary Session & Fireside Chat - Regulatory and Industry Insights & Lessons Learned Wrapping up the conference it is important to hear from regulatory leaders to help frame the strategy for the era ahead.  Lessons learned from organizations around the world will give individuals the most current insights for those difficult discussion back at your home base. 

      • Facilitating Development of Advanced Therapies
        Raj K. Puri, MD, Director, Division of Cellular & Gene Therapies
        CBER, FDA  
      • Industry and Regulatory Fireside Chat
        Raj K. Puri, MD, PhD, Director, Division of Cellular & Gene Therapies
        CBER, FDA
        Patricia Hughes, PhD, Branch Chief, Division of Microbiology Assessment
        CDER, FDA
        John Balchunas, Workforce Director National Institute for
        Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
        Lawrence Hill, CEO & VP Global Clinical Development
        Gan & Lee USA
        Maria Hoffman, Executive Director, Supply Chain Management
        Merck
      • Closing Remarks & Adjourn
        Joseph Famulare, Conference Chair, VP Global Compliance & External Collaboration
        Genentech

      Regulatory Updates on Biotechnological & Biological Products

      Regulatory Updates on Biotechnological and Biologic Products Regulatory expectations related to biotechnology and biological products are continually evolving both within mature and emerging regulatory agencies. This session will provide a snapshot of recent regulatory changes across the global landscape. Invited speakers will provide a sampling of some of the recent regulatory responses related to the ongoing COVID-19 pandemic, discuss the rapidly evolving regulatory landscape in China, and highlight some of the recent trends related to sterile products in the United States.

      • COVID-19 Pandemic Regulatory Responses
        Joseph Famulare, Vice President, Global Quality Compliance and External Relations Genentech, A Member of the
        Roche Group  
      • Update on Sterile Products and Change Management
        Richard Friedman, Deputy Director, Science & Regulatory Policy
        CDER, FDA  
      • Regulatory Requirement Differences Between China and US for Biologics & Biosimilars
        Lawrence A. Hill, PharmD, RPh, MBA, CEO
        Gan &Lee Pharmaceuticals USA
    • Quality Control Sessions

      Automation, Robotics and Digitalization in QC Labs

      Automation, Robotics and Digitalization in Biopharmaceutical QC Labs The goal of this session is to engage laboratory leaders, automation and informatics experts, regulators, and instrument/equipment/software vendors in rich discussions regarding the use of automation, robotics, and digital solutions to advance multiple dimensions of operational excellence in the pharma quality control laboratories.

      • Technology Solutions & Business Drivers for Moving from Manual to Automated Solutions in the Pharmaceutical QC Lab
        Jacqueline Larew, Senior Advisor-Global Quality
        Eli Lilly and Company
        Mark G. Schweitzer, Global AS&T and Scientific Initiatives
        Novartis  
      • QC Today and QC in the Future
        Vinny Browning III, Executive Director Commercial Attributes Sciences
        Amgen  
      • Case Study: Automation of Stability Data Reporting and Trend Analysis
        Janine Kuratli, Manager Data Analytics
        CSL Behring  
      • Case Study: Automated Technology Platform for Real-Time PCR-based Adventitious Agent Detection
        Sven M. Deutschmann, PhD, Head of Global ASAT
        Adventitious Agents    
      • Testing & Alternative Microbiological Methods, Global QC
        Sven M. Deutschmann, PhD, Head of Global ASAT
        Roche Diagnostics GmbH

      Single Use Technology Strategies

      Single Use Technology Strategies The approach to manufacture is never simple and now more and more hybridized. In this session experts share their latest findings and recommendations in SUT.  Given the movement toward personalized medicine even if you are not a single use proponent, getting ready for the future is important to your business.

      • Going from N-1 to Purified Product in a Closed and Connected Single-use Solution
        Pietro Perrone, PE Cytiva, Formerly GE Healthcare Life Hande Özgen, PhD,
        Scientist Cytiva, Formerly GE Healthcare Life  
      • Single-use Versus Stainless Steel Biomanufacturing Facilities: Are Hybrid Facilities the Best of Both Worlds?
        Lindsay Smart
        ZETA
    • Regulatory Harmonization Sessions

      Application of ICH Q12 Principles in Modern CMC Submissions

      Application of ICH Q12 Principles in Modern CMC Submissions This session brings together industry and regulatory agency representatives to discuss case studies involving the implementation of ICH Q12 principles in regulatory submissions to facilitate post-approval CMC changes in an efficient and predictable manner.

      • FDA Perspective on the Implementation of ICH Q12
        Pietro Perrone, PE Terrance Ocheltree, PhD, President
        PharmTree Consultants  
      • ICH Q12 and Beyond: The Journey Towards Regulatory Convergence in Product Life Cycle Management
        Nina Cauchon, PhD, Director, Regulatory Affairs – CMC
        Amgen Inc.
      • Application of ICH Q12, Established Conditions, and a Product Life Cycle Management Document to the Analytical Aspects of the 2019 FDA Q12 Pilot Program
        Michael Cohen, PhD, Research Fellow – Global CMC
        Pfizer  
      • Extended Panel Q&A/Discussion
        Nina Cauchon, PhD, Director, Regulatory Affairs – CMC
        Amgen Inc.
        Michael Cohen, PhD, Research Fellow – Global CMC
        Pfizer
        Andrew Chang, PhD, Vice President, Quality and Regulatory Compliance, Product Supply Quality
        Novo Nordisk

    Buy Now

    *ISPE Membership is required for these rates.


    2020 ISPE Continuous Manufacturing Workshop Sessions

    cmvw20

    Interest in continuous manufacturing of pharmaceuticals has exploded in the past few years, fueled by the recent regulatory approvals of the first few drug products to be manufactured by this emerging technology. The 2020 ISPE Continuous Manufacturing Workshop brought together industry practitioners, regulators and academics to discuss the recent successes and remaining challenges for continuous manufacturing of small molecule drug substances and drug products. The conference provided an in-depth view of the manufacturing technologies and regulatory approaches for successful development, implementation, and lifecycle management of continuous manufacturing both for new molecules and for batch to continuous conversions.

    If you missed the workshop, this is your opportunity to gain access to all of the educational content from the conference and view it on your own schedule. Get the biggest bang for your buck by purchasing the entire workshop in one package or review the list of sessions to purchase individual.

    2020 ISPE Continuous Manufacturing Virtual Workshop Sessions

    All purchases include access to the plenary sessions

      Per Session Package
    Member $170   $840    
    Nonmember   $239    $1,195  
    Government/Academia* N/A $500  
    Student* N/A $90  

    Conference Sessions

    • Continuous Manufacturing for Large Molecule

      Analytics Considerations for Continuous Manufacturing

      Analytics Considerations for Continuous Manufacturing This session will be a series of presentations related to analytics and release assays critical to successful implementation of CM. The session will include perspectives on emerging approaches for assessment of quality attributes, on release testing, and on the importance of process control and PAT.

      • Quality Considerations for the Multi-Attribute Method (MAM)
        Sarah Rogstad, Staff Fellow, Chemist
        FDA
      • Modern Microbiological Monitoring of Continuous Processing
        Cheryl Essex, Head of Microbiological Control for Biologic Drugs
        Sanofi
      • Integrating Analysis with Process Control for the Continuous Bioprocessing: Extending the Lifecycle Concept to Process Analytical Technologies
        Jose C. Menezes, PhD, President and CEO
        4Tune Engineering Ltd

      Current Status on CM for Biologics: Development to Clinical

      Speakers will provide insights on the current stage of deployment of CM for biological molecule clinical manufacturing from the point of view of process technologies, facility assets, and manufacturing operations. Examples of successes as well as challenges encountered will be shared.

      • The Biopharmaceutical Industry Emerging Continuous and Integrated Platform for Recombinant Protein Jon Coffman, PhD, Senior Director of Bioprocess Technology and Engineering AstraZeneca
      • Perspectives on the Development of Continuous Manufacturing for Biological Products
        Mark Brower, Principal Scientist
        Merck
      • Novel Technologies to Enable Continuous Manufacturing of Biologics
        Govind Rao, PhD, Director, Center for Advanced Sensor Technology
        University of Maryland, Baltimore County

      Implementation Approaches for Large Molecule

      Implementation Approaches for Large Molecule Continuous Manufacturing This session will focus on the integrated and continuous biomanufacturing process applied in the production of large molecules with experience shared by Sanofi, Pfizer and BI. Several areas will be discussed including leveraging the at-scale data to support comparability studies, as well as pre PPQ campaigns, and lifecycle process validation considerations.

      • Lifecycle Process Validation Considerations for Large Molecule Continuous Manufacturing
        Katherine Giacoletti, Partner
        SynoloStats LLC  
      • Leveraging ICB Technology for Novel Approaches to Process Performance Qualification
        Kevin Brower, Head of Purification Development
        US Sanofi
      • Development of an Integrated Manufacturing Process: The iSKID™
        Michael Jankowski, associate Research Fellow, Analytical R&D
        Pfizer Biotx Pharm Sci

      Perspectives on the Adoption and Implementation

      Perspectives on the Adoption and Implementation of Continuous ManufacturingThis session will include 3 highly regarded experts in the CM for biological molecules. These experts will share perspectives and experiences on the development and potential adoption of CM for large molecules.

      • Integrated Approach to Semi-Continuous Drug Substance Manufacturing
        Mehdi Ghodbane, PhD, Downstream Process Development, Medicinal Science & Technology
        GlaxoSmithKline  
      • N-1 Perfusion from Development through GMP Implementation
        Gene Schaefer, Senior Director Large Molecule API Development
        Janssen
      • Sanofi’s MA Digitalized Facility, an Ecosystem of the Future
        Navin Tiwari, Director, Head of Digital Shop Floor & Automation
        Sanofi
    • Continuous Manufacturing for Small Molecule

      Advances in Continuous Manufacturing for Small Molecule

      Advances in Continuous Manufacturing for Small Molecule While continuous processes started with a few continuous steps, the maximal value of continuous manufacturing will be gained from increased integration. Several recent processes demonstrate this value. This session will focus on actual industrial processes, emphasizing the technical and business advantages of integration. Advances in the integration of unit operations, independently for API and drug product as well as the end-to-end integration of the two will be discussed over the course of the session.

      • Full Integration of Continuous Manufacturing
        Sal Mascia, PhD, President and CEO
        CONTINUUS
      • Mighty Machines; Integrating Design of Chemical Processes and Flow Reactor Systems
        Matthew M. Bio, PhD, President and CEO
        Snapdragon Chemistry
      • Enabling End to End Continuous Manufacturing: FDA Perspective
        Sharmista Chatterjee, PhD, Division Director
        OPMA, OPQ/CDER

      Emerging Technologies

      Emerging Technologies The session brings together industrial case studies from practitioners who have delivered innovative solutions to enable the adoption of continuous processing within their companies.

      • Commercializing New Chemical Technologies in Flow
        Moiz Diwan, PhD, Director, Head of Enabling Technology Group
        AbbVie  
      • Continuous Processing for the Manufacture of Active Pharmaceutical Ingredients
        Martin Johnson, PhD, Sr. Engineering Advisor
        Eli Lilly & Company
      • The Use of Kinetic Modelling to Define a Design Space for a Continuous Process
        Peter Shapland, PhD, Scientific Leader, R&D Medicinal Science & Technology
        GSK Stevenage

      Expert Roundtable

      Expert Roundtable: How do we realize the full potential for Small Molecule in the new decade? Panel discussion with experts in the area of small molecule continuous manufacturing will discuss the technical, regulatory, and business hurdles for continuous manufacturing. This session will highlight CM as a continuum from E2E to hybrid approaches, including the need for "batch steps" for some products, requirement differences which can be a hindrance to global implementation of advanced technologies enabled by CM such as PAT, RTRT, and modeling; and why E2E CM may or may not be the optimal solution.        

      • Malcolm Berry, PhD, CEO & Founder MB
        Chemistry Consulting, Ltd.    
      • Sharmista Chatterjee, PhD, Division Director OPMA,
        OPQ/CDER  
      • Gabriella Dahlgren, PhD, Manager, Strategy Deployment
        Janssen Supply Group LLC      
      • Elizabeth Grieco, Director Vertex  
      • Michael O’Brien, PhD, Founder and President NGT
        BioPharma Consultants

      Success Stories From Small Molecule Drug Product

      Success Stories From Small Molecule Drug Product Significant progress in CM implementation has been made over the last ten years. From fundamental studies within academia to global drug product CM approvals, CM represents a paradigm shift within the industry that will continue to grow with time. In this session, success stories from some of the early adopters and implementers will be shared which include regulatory, technical, and business-related achievements in the hope that it will encourage others to join the CM movement!

      • Leveraging Continuous Manufacturing to Enable Real Time Release Testing
        Joseph Medendorp, Senior Director, Technical Operations
        Vertex  
      • Particle Design and Engineering to Enable Continuous Direct Compression Manufacturing Processes
        Jeremy Merritt, PhD, Principal Research Scientist, Particle Design Lab – Small Molecule Design & Development
        Eli Lilly and Company Janssen
      • CM-strategy: A Story of Multiple Platforms From R&D to Commercial
        Jeroen Geens, Engineering Technical Director – New Platforms
        Janssen
    • Plenary Sessions - Bonus Content Included

      A New Decade for Continuous Manufacturing

      A New Decade for Continuous Manufacturing Continuous manufacturing for pharmaceutical and biopharmaceutical manufacturing is still in its infancy with only a limited number of products approved within the past 5 years. As we begin the third decade of the third millennium, we anticipate that bio/pharmaceutical manufacturing will continue to get smaller, faster, and smarter. In this opening conference session, a broad array of speakers from industry, academia, and regulatory agencies will provide their views on the state of continuous bio/pharmaceutical manufacturing today and predictions for its future.

      • Welcome and Opening Remarks
        Christine M. V. Moore, PhD, Conference Chair; Global Head and Executive Director, GRACS CMC Policy
        Merck  
      • Speaker Introductions
        Sharmista Chatterjee, PhD, Division Director
        OPMA, OPQ/CDER
      • ICH Q13 Guidance – Continuous Manufacturing of Drug Substance and Drug Product
        JRapti Madurawe, PhD, Division Director
        FDA/CDER/OPQ/OPPQ
      • End to End Collaboration to Transform Biopharmaceutical Development & Manufacturing
        John Erickson, PhD, Senior Fellow,
        National Institute for Innovation in Manufacturing Biopharmaceuticals NIIMBL
      • Perspectives on the Implementation of Continuous Manufacturing 
        Sarah O’Keefe, PhD, VP Small Molecule Design and Development
        Eli Lilly and Company

    Buy Now

    *ISPE Membership is required for these rates.

  • Expanded Online Training
    ISPE is bringing the intensity of its in-person courses to the big screen -- your computer.  With ISPE Online Expanded Courses, you can take ISPE's signature training, the type usually delivered over two to three days in a distant classroom, from your home or office. View Courses
  • General Industry Knowledge Courses
    These courses offer general industry knowledge while providing an industry overview, historical background and the basic building blocks to get you started and understand more advanced and specific industry topics. View Courses
  • GMP Courses
    Learn the U.S. Food and Drug Administration's Systems-based GMP Inspection Approach, which is widely accepted as the best way to conduct business. View Courses
  • Fundamental Industry Knowledge Courses
    Our longstanding online courses can help you meet your annual training requirements and improve your career. View Courses
  • Online Learning Webinars
    Using the expertise of our global membership we developed numerous pre-recorded webinars for over 19-topic specific areas to meet the needs of global pharmaceutical manufacturing professionals. Many webinars provide in-depth knowledge through case studies or use conference seminar presentations to share best practices. View Courses